REGULATORY
CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
By Yoshinori Sagehashi April 19, 2019
Japan is to not use its new cost-effectiveness assessment (CEA) scheme for reimbursement decisions - at least for now - but this would give no respite for the industry as budget examiner Iichiro Yoshino says…

LATEST

April 19, 2019
Novartis Pharma expects “around two to three” institutions in Japan to initially provide its CAR-T cell therapy Kymriah (tisagenlecleucel), but it hopes to gradually increase the number of certified sites that can offer the treatment with the highest standards, Japan…
April 19, 2019
Despite its recent downsizing in Japan, Boehringer Ingelheim will remain “a major employer” in the country by deploying staffers where and when necessary in keeping with changes in its local portfolio, the company’s global pharma…
April 19, 2019
The number of contract sales reps in Japan fell by 11.5% compared to the previous year to 3,110 as of October 2018, the Japan Contract Sales Organization Association (JCSOA) said on April 17. Contract reps…
By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

By Yoshinori Sagehashi

Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…

Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA